Navigation Links
Correcting sickle cell disease with stem cells
Date:9/28/2011

Using a patient's own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.

The research team cautions that the work, done only in the laboratory, is years away from clinical use in patients, but should provide tools for developing gene therapies for SCD and a variety of other blood disorders.

In an article published online August 31 in Blood, the researchers say they are one step closer to developing a feasible cure or long-term treatment option for patients with SCD, which is caused by a single DNA letter change in the gene for adult hemoglobin, the principle protein in red blood cells needed to carry oxygen. People who inherited two copies -- one from each parent -- of the genetic alteration, the red blood cells are sickle-shaped, rather than round. The misshapen red blood cells clog blood vessels, leading to pain, fatigue, infections, organ damage and premature death.

Although there are drugs and painkillers that control SCD symptoms, the only known cure -- achieved rarely -- has been bone marrow transplant. But because the vast majority of SCD patients are African-American and few African-Americans have registered in the bone marrow registry, it has been difficult to find compatible donors, says Linzhao Cheng, Ph.D, a professor of medicine and associate director for basic research in the Division of Hematology and also a member of the Johns Hopkins Institute for Cell Engineering. "We're now one step closer to developing a combination cell and gene therapy method that will allow us to use patients' own cells to treat them."

Using one adult patient at The Johns Hopkins Hospital as their first case, the researchers first isolated the patient's bone marrow cells. After generating induced pluripotent stem (iPS) cells -- adult cells that have been reprogrammed to behave like embryonic stem cells -- from the bone marrow cells, they put one normal copy of the hemoglobin gene in place of the defective one using genetic engineering techniques.

The researchers sequenced the DNA from 300 different samples of iPS cells to identify those that contained correct copies of the hemoglobin gene and found four. Three of these iPS cell lines didn't pass muster in subsequent tests.

"The beauty of iPS cells is that we can grow a lot of them and then coax them into becoming cells of any kind, including red blood cells," Cheng said.

In their process, his team converted the corrected iPS cells into immature red blood cells by giving them growth factors. Further testing showed that the normal hemoglobin gene was turned on properly in these cells, although at less than half of normal levels. "We think these immature red blood cells still behave like embryonic cells and as a result are unable to turn on high enough levels of the adult hemoglobin gene," explains Cheng. "We next have to learn how to properly convert these cells into mature red blood cells."

Only one drug treatment has been approved by the FDA for treatment of SCD, hydroxyurea, whose use was pioneered by George Dover, MD, the chief of pediatrics at the Johns Hopkins Children's Center. Outside of bone marrow transplants, frequent blood transfusions and narcotics can control acute episodes.


'/>"/>
Contact: Vanessa McMains
vmcmain1@jhmi.edu
410-502-9410
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Sickle cell trait is not risk factor for kidney disease
2. Schools failing pupils with sickle cell disease
3. Nitric oxide impacts source of sickle cell pain crisis
4. ENERCA clinical recommendations for sickle cell disease management and prevention in children
5. Young black athletes with sickle cell trait might be susceptible to sudden death
6. Sickle Cell May Be Hidden Danger to Young Athletes
7. 2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients
8. Georgia Tech hosts sickle cell disease symposium
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Sickle cell patients should be better monitored for constipation prevention
11. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... ... corporate identity and website at its “Transforming Outcomes” User Conference in Las Vegas ... reflect i2i’s ongoing success to set the market standard for meaningful population health ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... Church, VA (PRWEB) , ... May 24, 2016 , ... ... 14-15, 2016 · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to ... is unlikely that human error will ever be totally eliminated, many human performance problems ...
(Date:5/24/2016)... ... ... Regenerative Medicine is being transformed by ongoing research and clinical findings at ... results as have been achieved with Okyanos Cell Therapy are paving the ... patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric Duckers, MD, PhD, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... or injury that focuses on repairing the musculoskeletal and neuromuscular systems of the ... on functional restoration, NYDNRehab began providing treatments for physical therapy in New York, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... den Markt gebracht, die es Ärzten erlaubt, ihre ... zu behandeln: MDLinking kombiniert Live Streaming mit einer ... Umfeld zu kommunizieren. Mediziner in Europa, Afrika, Asien ... sich bereits für die Plattform registriert. ...
(Date:5/24/2016)... CHRISTCHURCH, New Zealand , May 24, 2016 ... scanning and informatics solutions for the healthcare sector, has been ... the New Zealand Hi-Tech Awards 2016. Dr ... a fantastic acknowledgement for our team.  It,s really good to ... the burden healthcare internationally. Our products are used in 35 ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology: